Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera, Inc. develops and commercializes cell-free DNA and genetic testing for oncology, women’s health and organ health. Company updates commonly cover financial results, revenue trends, laboratory operations and publications supporting tests such as Signatera, Prospera, Panorama and Horizon.
Recurring news also includes oncology molecular residual disease applications, clinical evidence presented at medical meetings, transplant rejection surveillance data, collaborations using Natera assays in drug trials, and patent or litigation developments tied to its MRD technology. The company reports through CLIA-certified and CAP-accredited laboratory operations and through Foresight Diagnostics, its subsidiary.
Natera (NASDAQ:NTRA) announced a collaboration to support a Phase 1 clinical trial sponsored by Kupando Therapeutics in Germany, evaluating Kupando’s lead immunotherapy candidate KUP-101 in patients with advanced tumors across multiple skin cancers. Natera’s Latitude tissue-free molecular residual disease (MRD) assay will be used to monitor serial circulating tumor DNA (ctDNA) dynamics as part of treatment response assessment at multiple timepoints.
According to Natera, Kupando has successfully dosed the first patient, and its safety committee has approved continued enrollment at activated oncology centers. The trial will explore KUP-101’s innate immune activation approach and use Latitude to generate molecular response insights across diverse solid tumors.
Natera (NASDAQ:NTRA) reported second quarter 2026 revenues of $752.8 million, up 37.7% from $546.6 million a year earlier, driven by higher test volumes and improved average selling prices. Gross margin was 64.5%, versus 63.4% in Q2 2025, with non-GAAP gross margin up about 50 bps sequentially excluding revenue accrual true-ups.
The company processed about 1,043,900 tests in Q2 2026, including 296,700 oncology tests, a 57.2% year-over-year oncology increase. Net loss narrowed to $67.0 million ($0.47 per share) from $100.9 million ($0.74 per share). Natera ended the quarter with $1.09 billion in cash, cash equivalents and restricted cash and $80.3 million in outstanding debt. Full-year 2026 revenue guidance was raised by $100 million at the midpoint to $2.85–$2.91 billion, with expected gross margin of 64–66% and positive cash flow.
Natera (NASDAQ: NTRA) has submitted Signatera, its personalized molecular residual disease (MRD) test, to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for approval as a companion diagnostic in muscle-invasive bladder cancer (MIBC). The MIBC application is supported by data from IMvigor011, a randomized, double-blind Phase 3 trial.
According to Natera, this step builds on Signatera’s recent PMDA approval in colorectal cancer, where it became Japan’s first PMDA-approved MRD test, and on U.S. FDA approval of Signatera CDx for adjuvant atezolizumab in MIBC, alongside an NCCN Category 1 recommendation for MRD-guided use.
Natera (NASDAQ:NTRA) will release its second quarter 2026 financial results for the period ended June 30, 2026, after the market close on August 6, 2026. The company will host an earnings conference call and live webcast at 1:30 p.m. PT (4:30 p.m. ET).
Natera (NASDAQ: NTRA) reported results from a prospective, multicenter Merkel cell carcinoma (MCC) study published in JAMA Dermatology, showing its Signatera™ minimal residual disease (MRD) test outperformed the Merkel cell polyomavirus antibody test (AMERK) for recurrence prediction and monitoring.
In 169 MCC patients, Signatera showed higher sensitivity (90% vs 55%), stronger recurrence prediction (hazard ratio difference 6.6; p < 0.001), and higher positive and negative predictive values than AMERK. Among patients where both tests detected recurrence, Signatera identified relapse earlier, with a median lead time of 5.1 months vs 2.1 months. According to Natera, Signatera is validated across both virus-positive and virus-negative MCC and retains accuracy after immunotherapy, supporting its role as a universal biomarker for surveillance.
Natera (NASDAQ: NTRA) reported that the finalized MolDx local coverage determination (LCD L40060) for molecular testing for solid organ allograft rejection significantly expands Medicare coverage for its Prospera transplant surveillance tests. The policy, expected to take effect on August 30, 2026, increases covered surveillance test frequencies across kidney, heart, and lung transplantation.
According to Natera, the LCD now allows up to 6 kidney tests in year 1 and 4 per year in years 2–3, 12 heart tests in year 1 and 4 per year in years 2–3, and 12 lung tests in year 1 and 4 per year in years 2–3. “For-cause” coverage remains unchanged. The final LCD improves on the July 2025 draft, which had proposed lower test frequencies, and follows supportive comments from leading transplant medical societies.
Natera (NASDAQ:NTRA) announced that its personalized MRD test Signatera received EU IVDR Class C certification, one of the strictest regulatory standards for in vitro diagnostics.
The certification covers adjuvant and surveillance use across multiple solid tumors and lymphomas and supports continued EU availability beyond the 2028 IVDD transition deadline. It follows recent FDA and PMDA approvals for Signatera indications in the United States and Japan.
Natera (NASDAQ:NTRA) reported new JAMA Oncology data from 298 patients in the GALAXY trial, showing its Signatera MRD test helped predict overall survival benefit from adjuvant chemotherapy in resected colorectal liver metastases.
MRD-positive patients receiving chemotherapy had improved DFS and OS, while MRD-negative patients showed no observed survival benefit.
Natera (NASDAQ:NTRA) and Aveta Biomics announced a strategic partnership for AVTA 30-01, a global Phase 3 registrational trial of oral immunotherapy APG-157 in locally advanced head and neck squamous cell carcinoma.
Serial Signatera MRD testing will assess molecular response in 826 patients across multiple regions, with enrollment expected to begin in 2H 2026. APG-157 holds FDA Fast Track and Orphan Drug Designations.
Natera (Nasdaq:NTRA) and Eledon (Nasdaq:ELDN) formed a strategic partnership to use Natera’s Prospera kidney transplant assessment test in Eledon’s planned Phase 3 trial of tegoprubart.
Prospera will be the exclusive donor-derived cell-free DNA monitoring assay in a ~600-patient kidney transplant study expected to start in late 2026.